NeurologyNovartis
Novartis Reports Phase 3 ASCLEPIOS Results for Kesimpta in Relapsing Multiple Sclerosis
BMI
Biotechnology Media Insights
Editorial Team · September 5, 2023
Novartis announces Phase 3 ASCLEPIOS trial results showing Kesimpta significantly reduces relapse rates vs teriflunomide in relapsing multiple sclerosis.
Novartis today announced results from the Phase 3 ASCLEPIOS I and II trials evaluating Kesimpta (ofatumumab) versus teriflunomide in patients with relapsing multiple sclerosis. The trials met their primary endpoints, demonstrating significant reductions in annualized relapse rates with Kesimpta compared to teriflunomide.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.